Seeking Alpha

Shares of ArQule (ARQL +14.2%) roar to life after the firm announces that its Tivantinib liver...

Shares of ArQule (ARQL +14.2%) roar to life after the firm announces that its Tivantinib liver cancer drug met its primary endpoint in Phase II clinical trials.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs